0 items
Show in Cart Page
img

No items found

View Products
Discount 0
Total $0.00
Checkout
img

No Categories Found

TELEGRAM US @Omegachemist25

Track Order
img English
img
img
img
img

Buy Keytruda (Pembrolizumab) Online

$3,600.00 $4,300.00

  • (0)

Keytruda (Pembrolizumab) is an innovative immunotherapy treatment designed to enhance the body's immune response against cancer. Approved for various types of cancer, including melanoma, lung cancer, and more, Keytruda works by blocking the PD-1 pathway, allowing immune cells to effectively target and destroy cancer cells. With its proven efficacy and safety profile, Keytruda offers hope for patients seeking advanced cancer treatment options.

Categories
SKU KTD63736OM
Quantity
  • Specification
  • Description
  • Reviews
  • Active Substance Pembrolizumab, 25mg/mL, preservative-free.
  • Mechanism Binds to PD-1 receptor, blocking interactions with PD-L1 and PD-L2 to activate T-lymphocytes.
  • Formulation Single-dose vials (100 mg/4 mL).
  • Administration Intravenous (IV) infusion (30 min) or subcutaneous injection (1–2 min for Qlex).
  • Storage 2°C to 8°C (36°F to 46°F), do not freeze.
  • Duration Until disease progression or unacceptable toxicity, or up to 24 months.
  • Melanoma/NSCLC/HNSCC 200 mg every 3 weeks or 400 mg every 6 weeks.
  • Pediatric (up to 200 mg) every 3 weeks.
  • Strengths 395 mg/2.4 mL or 790 mg/4.8 mL.
  • Time 1–2 minute injection.

Buy Keytruda (Pembrolizumab) Online
Keytruda (pembrolizumab) is an intravenous (IV) medication used to treat the following types of cancer:

  • Advanced non-small cell lung cancer
  • High-risk non-muscle invasive bladder cancer
  • Advanced MSI-H/dMMR colorectal cancer
  • Advanced triple-negative breast cancer
  • Advanced cervical cancer
  • Advanced liver cancer
  • Cutaneous squamous cell carcinoma
  • Melanoma
  • Advanced urothelial bladder cancer
  • Microsatellite instability-high colorectal cancer
  • Classical Hodgkin lymphoma
  • Advanced MSI-H/dMMR endometrial cancer
  • Advanced Merkel cell carcinoma
  • Head and neck squamous cell carcinoma
  • Kidney cancer
  • High-risk early-stage triple-negative breast cancer
  • Advanced gastric cancer
  • Primary mediastinal B-cell lymphoma
  • Advanced esophageal cancer




Directions

Your healthcare provider will determine the right dose of Keytruda for you and how many treatments you should receive. Your healthcare provider will administer the medication through an IV over 30 minutes. Keytruda is usually administered every 3 or 6 weeks.

Talk to your doctor about any questions or concerns you may have about the medication.

Ingredients

The active ingredient in Keytruda is pembrolizumab. Inactive ingredients include L-histidine, polysorbate 80, sucrose, and Water for Injection.

Contraindications

There are no contraindications according to the Keytruda Prescribing Information.

Cautions

  • Before you begin treatment with Keytruda, inform your doctor of:
    • All the prescription and over-the-counter medications you take
    • Your allergies
    • Your medical history and current health problems
    • Your pregnancy or breastfeeding status
  • Keytruda can cause immune system problems that can be severe or life-threatening. These include pneumonitis, colitis, hepatitis, endocrinopathies, nephritis with kidney impairment, dermatologic reactions, and solid organ transplant rejection.
  • Keytruda can cause infusion-related reactions, including hypersensitivity and anaphylaxis.
  • Keytruda can cause serious or life-threatening complications in patients who receive allogeneic hematopoietic stem cell transplantation (HSCT). These reactions include hyperacute graft-versus-host-disease (GVHD), acute GVHD, chronic GVHD, hepatic veno-occlusive disease (VOD) and can occur after intervening therapy between Keytruda and allogeneic HSCT.
  • Patients with multiple myeloma should not receive Keytruda in combination with a thalidomide analogue and dexamethasone unless they are participants in controlled clinical trials.
  • Keytruda can cause harm to an unborn baby. Women of childbearing age should use an effective method of birth control.

Side Effects

Common Keytruda side effects include fatigue, musculoskeletal pain, rash, diarrhea, fever, cough, decreased appetite, itching, shortness of breath, constipation, pain, stomach pain, nausea, and hypothyroidism. Other side effects may also occur. Call your doctor right away if you develop side effects that are bothersome or persistent.

Reference:

Keytruda (pembrolizumab) injection, for intravenous use. Whitehouse Station, NJ: Merck & Co., Inc.; 2023.


No reviews yet

Login to review.

We may use cookies or any other tracking technologies when you visit our website, including any other media form, mobile website, or mobile application related or connected to help customize the Site and improve your experience. learn more

Allow